Herpes simplex virus seroprevalence and seroconversion among active duty US air force members with HIV infectionJared Cohen, Jason F. Okulicz, Amanda Sellers et al.|Journal of Clinical Virology|2015Cited by 10
The Potential for Selective Cyclin-Dependent Kinase 4/6 Inhibition in the Therapy for Head and Neck Squamous Cell CarcinomaDouglas R. Adkins, Peter Oppelt, Jessica Ley et al.|The Cancer Journal|2022Cited by 7
Palbociclib + cetuximab versus cetuximab in patients with <i>CDKN2A</i>-altered, anti-PD-1 resistant, HPV-negative head and neck squamous cell carcinoma (HNSCC): A phase 3 trial.Jessica Ley, Douglas R. Adkins, Jared Cohen et al.|Journal of Clinical Oncology|2023Cited by 5
Tazemetostat, a selective EZH2 inhibitor, with pembrolizumab as treatment of anti-PD-1 resistant head and neck squamous-cell carcinoma (HNSCC): A phase 1-2 trial.Sidharth V. Puram, Douglas R. Adkins, Erik Shannon et al.|Journal of Clinical Oncology|2023Cited by 4
Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.Jared Cohen, Douglas R. Adkins, Jessica Ley et al.|Journal of Clinical Oncology|2023Cited by 4